STOCKS TELEGRAPH

Tag: NRBO STOCK PRICE

  • Continued Pre-Market Rally For NeuroBo Pharmaceuticals’ (NRBO) Stock

    Continued Pre-Market Rally For NeuroBo Pharmaceuticals’ (NRBO) Stock

    As the market begins today, shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) seem to be continuing their prior session’s gain, propelled by news of recent and successful stock transactions. The pre-market trading activity for NRBO shares showed a 12.91% increase in value, closing at $4.81.

    Equity Deals And Issues

    NeuroBo Pharmaceuticals (NRBO) has completed its previously announced private placement, in which 4,325,701 shares of common stock were sold for $3.93 a share. The business concurrently issued and sold 763,359 shares of ordinary stock at the same price through a registered direct offering.

    NeuroBo also issued unregistered Series A and Series B warrants to acquire up to 5,089,060 and 7,633,591 shares of common stock, respectively, in addition to the equity transactions. The exercise price of each set of warrants is $3.93 per share, and they can be exercised only with stockholder permission.

    The Series A warrants will expire sixty days after the public release of a favorable Phase 1 multiple ascending dose (MAD) data readout for DA-1726, or twelve months after the stockholder approval. The Series B warrants will expire either six months after the Phase 1 Part 3 data readout for DA-1726 is publicly announced or five years after the stockholder approval.

    Promising Pre-Clinical Data For DA-1726

    Recently, NeuroBo disclosed pre-clinical data indicating that DA-1726 demonstrated superior results in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide in pre-clinical models. This data was presented by Tae-Hyoung Kim, the lead research scientist at Dong-A ST Research Center, at the American Diabetes Association (ADA) 84th Scientific Sessions held from June 21-24 in Orlando, Florida.

    The presented data highlights that DA-1726 distinguishes itself from other obesity drugs in the same class, likely due to its unique GLP-1 and glucagon receptor activity ratio. In obese mouse models, DA-1726 significantly reduced cholesterol levels and induced superior weight loss compared to survodutide, while also exhibiting better glucose-lowering effects. Notably, DA-1726 showed superior weight loss and preservation of lean body mass compared to survodutide.

  • Why did NeuroBo Pharmaceuticals Inc. (NRBO) stock surge on Monday?

    Why did NeuroBo Pharmaceuticals Inc. (NRBO) stock surge on Monday?

    NeuroBo Pharmaceuticals Inc. (NRBO) shares surged 41.49% in after-hours on Monday, July 19, 2021, and closed at $3.99 per share. Earlier in the morning session, NRBO’s stock gained 3.30% to close Monday’s session at $2.82 per share. NRBO shares have fallen 67.47% over the last 12 months, and they have moved down 3.75% in the past week. Over the past three months, the stock has lost 9.62%, while over the past six months, it has shed 53.23%.

    New Board members elected

    On July 12, 2021, NeuroBo Pharmaceuticals, Inc announced the results of the elections conducted at its Annual Meeting of Shareholders, which was held on Friday, July 9, 2021, during which Hyung Heon Kim and Andrew I. Koven were elected to the Company’s Board of Directors.

    The NeuroBo Board now consists of seven directors, six of whom are considered independent directors.

    Recent financial results announcement

    On May 17, 2021, NeuroBo Pharmaceuticals, Inc reported its financial results for the first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • In Q1 2021, Research and development expenses were approximately $1.1million compared with approximately $2.2 million in Q1 2020.
    • General and administrative expenses were $2.2 million in Q1 2021 compared to $2.6 million in Q1 2020.
    • The company suffered a net loss of $3.3 million, or $0.15per basic and diluted share in Q1 2021 compared to a net loss of $4.8 million, or $0.30 per basic and diluted share in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of $13.0 million compared with $10.1 million as of December 31, 2020.

    FY 2020 financial results announcement

    On April 15, 2021, NeuroBo Pharmaceuticals, Inc announced financial results for the year ended December 31, 2020.

    FY2020 financial highlights

    • Research and Development expenses were approximately $4.5 million for the year ended December 31, 2020, as compared to approximately $5.3 million for the year ended December 31, 2019.
    • In FY 2020, general and administrative expenses were $7.8 million compared to $2.7 million for the year ended December 31, 2019.
    • The company reported a net loss of $29.7 million, or $1.83per basic and diluted share in FY 2020 compared to a net loss of $21.3 million, or $4.08 per basic and diluted share in FY 2019.
    • As of December 31, 2020, NeuroBo Pharmaceuticals had cash and cash equivalents of $10.1 million compared with $13.9 million as of December 31, 2019.

    Conclusion

    Well, as of this writing, we have no recent news or development which could be the reason behind its exceptional performance on Monday. In the absence of any current news, it is difficult for us to predict its performance in the coming days.